Natreon Healthy Skin Study - PrimaVie Supplement

This study will demonstrate the ability of the oral supplement, PrimaVie® to improve skin microperfusion, hydration, elasticity and barrier function. 45 females will be enrolled in 1 of 3 arms where they will receive either 125 mg PrimaVie, 250 mg PrimaVie or placebo (control) to take twice daily for 14 weeks.

Inclusion Criteria: * Subjects willing to discontinue any dietary or nutritional supplements, other than a general multivitamin, starting two weeks before onset of study and also during the study. * Subjects must be willing to maintain their present diet with no major changes throughout the study. * Subjects must be willing to take the dietary supplements as required by the study protocol twice daily. * Female subjects must be between the ages of 30 to 65 years of age * Subjects must provide written informed consent and are willing to comply with all study procedures. Exclusion Criteria: * Any dermatological disorder that may interfere with the accurate evaluation of the subject's skin. * Subjects who are pregnant, breast feeding, or planning a pregnancy. * Clinically significant unstable medical disorders. * History of, diabetes, heart or kidney disease * History of a psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study. * Any skin disease in the area of the upper inner arm where the biopsies will be obtained. * Currently taking the following medications: * Steroids * Beta-blockers * Immunosuppressant's * Hydochlorothiazide, * Statins * Aspirin * ACE Inhibitors * Muscle relaxants * Stimulants * Prisoners * Males